© The Canadian Journal of Urology™; 19(Supplement 1); October 2012
53
Emerging therapies: what’s new is old and what’s old is new
References
1.
Barkin J. Benign prostatic hyperplasia and lower urinary tract
symptoms: evidence and approaches for best casemanagement.
Can J Urol
2011;18(
Suppl 1):14-19.
2.
Greenspan MB, Barkin J. Erectile dysfunction and testosterone
deficiencysyndrome:the“portaltomen’shealth”.
CanJUrol
2012;
19(
Suppl 1):18-27.
3.
Kapoor A. Benign prostatic hyperplasia (BPH) management in
the primary care setting.
Can J Urol
2012;19(
Suppl 1):10-17.
4.
Nickel JC, Mendez-Probst CE, Whelan TF, Paterson RF, Razvi
H. 2010 Update: Guidelines for the management of benign
prostatic hyperplasia.
5.
Hatano A, Takahashi H, Tamaki M, Komeyama T, Koizumi T,
TakedaM. Pharmacological evidence of district a1-adrenoceptors
subtypes mediating the contraction of human urethra and
peripheral artery.
Br J Pharmacol
1994;113(3):723-728.
6.
Barkin J. Medical management of BPH.
Perspectives in Cardiology
1993;
Suppl:25-32.
7.
Tatemichi S, Kobayashi K, Maezawa A et al. a1-Adenoceptor
subtypeselectivityandorganspecificityofsilodosin(KMD-3213).
Yakugaku Zasshi
2006;126:209-216.
8.
Christopher R. Chapple, Francesco Montorsi, Teuvo LJ et al
on behalf of the European Silodosin Study Group. Silodosin
therapy for lower urinary tract symptoms inmenwith suspected
benign prostatic hyperplasia: results of an international
randomized, double-blind, placebo- and active-controlled
clinical trial performed in Europe.
Eur Urol
2011;59(3):342–352.
9.
Rosen R, Altwein J, Boyle et al. Lower urinary symptoms and
male sexual dysfunction: the multinational survey of the aging
male (MSAM-7)
Eur Urol
2003;44(6):637-649.
10.
Donatucci CF, Brock GB, Goldfischer ER et al. Tadalafil
administered once daily for lower urinary tract symptoms
secondary to benign prostatic hyperplasia: a 1-year, open label
extension study.
BJU Int
2011;107(7):1110-1116.
11.
DellabellaM, Milanese G, Muzzonigro G. Efficacy of tamsulosin
in themedical management of juxtavesical ureteral stones.
J Urol
2003;170(6
Pt 1):2202-2205.
12.
Itoh Y, Okada A, Yasui T et al. Efficacy of selective a1A
adrenoceptor antagonist Silodosin in the medical expulsive
therapy for ureteral stones.
Int J Urol
2011;18(9)672-674.
13.
McNaughton Collins M. The impact of chronic prostatitis/
chronic pelvic pain syndrome on patients.
World J Urol
2003;21(2)
86-89.
14.
Nickel JC, Narayan P, McKay J, Doyle C. Treatment of chronic
prostatitis/chronic pelvic pain syndrome with tamsulosin:
a randomized double blind trial.
J Urol
2004;171(4):1594-1597.
15.
Nickel JC, O’Leary MP, Lepor H et al. Silodosin for men with
chronic prostatitis/chronic pelvic pain syndrome: results of a
phase II multicenter, double-blind, placebo controlled study.
J Urol
2011;186(1):125-131.
16.
Radomski SB, Barkin J. Medical management of overactive
bladder.
Can J Urol
2012;19(
Suppl 1):2-9.
17.
Takasu T, Ukai M, Sato S et al. Effect of (R)-2-(2-aminothiazol-
4-
yl)-4’-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide
(
YM178), a novel selective beta3-adrenoceptor agonist, on
bladder function.
J Pharmacol Exp Ther
2007;321(2):642-647
18.
Gomella LG Lallas CD, Perkel R et al. Uropharmacology in
primary care: 2010 update.
Can J Urol
2010;17(
Suppl 1); 35-51.
19.
Rehsia S, Shayegan B. PSA implications and medical
management of prostate cancer for the primary care physician.
Can J Urol
2012;19(
Suppl 1):28-35.
20.
Barkin J. PSA and the family physician.
Can J Urol
2011;18
(
Suppl 1):20-23.
21.
Liu XS, Folia C, Gomella LG. Pharmacology for common
urologic diseases: 2011 review for the primary care physician.
Can J Urol
2011;18(
Suppl 1):24-38.
22.
Saad F, Gleason DM, Murray DM et al. Long term efficacy of
zoledronic acid for the prevention of skeletal complications in
patients with metastatic hormone refractory prostate cancer.
J Natl Cancer Inst
2004;96(11):879-882.
23.
Percival RC, UrwinGH, Harris S et al. Biochemical and histologic
evidence that carcinoma of the prostate is associated with
increased bone resorption.
Eur J Surg Oncol
1987;13(1):41-49.
24.
Fizazi K, Carducci M Smith M et al. Denosumab versus
zoledronic acid for treatment of bone metastases in men with
castrate-resistant prostate cancer: a randomized, double blind
study.
Lancet
2011;377(9768):813-822.
25.
de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and
increased survival in metastatic prostate cancer.
N Engl J Med
2011;364(21):1995-2005.
26.
Scher HI, Fizazi K, Saad F et al. Increased survival with
enzalutamide inprostate cancer after chemotherapy.
NEngl JMed
2012
DOI:10.1056/NEJMoa 1207506.
Disclosure
Dr. Jack Barkin has been a clinical investigator, speaker
and medical advisory board member and consultant
for Abbott, Lilly, Bayer, Paladin, Watson Pharma, Bayer,
AstraZeneca , Astellas, Solvay, Pfizer and Triton.
Dr. Christine Folia has no potential conflict of interest.
